Vipin Garg

Late clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics that address serious metabolic and liver diseases. The Company’s lead product candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), alcohol-associated liver disease (ALD) and obesity. Pemvidutide has successfully completed multiple Phase 2 trials and is ready to enter Phase 3 registrational trials. For more information, please visit www.altimmune.com. • Identified and negotiated a strategic transaction with Spitfire Pharma, enabling Altimmune to expand its product portfolio through acquisition of a novel GLP-1/Glucagon dual receptor agonist (pemvidutide) for the treatment of MASH, obesity and other metabolic disorders. • Completed multiple financings, raising over $600M in capital for the Company. • Secured non-dilutive funding from Biomedical Advanced Research and Development Authority (BARDA) and Department of Defense (DoD). • Expanded the management team and the board, including research, clinical and commercial leaders formerly from large pharma.

Built a commercial-stage biopharmaceutical company with therapeutic products developed and manufactured utilizing company's proprietary technology platform. Responsible for raising over $250M in capital, including a highly successful IPO in 2015. Grew the Company from 50 to nearly 300 employees, including a fully integrated manufacturing operation and commercial infrastructure. Led the FDA approvals and commercial launches of three branded products, including Adzenys XR-ODT and Cotempla XR-ODT, the first XR-ODT medications for the treatment of ADHD. • Oversaw all corporate strategic planning, R&D, regulatory affairs, manufacturing, business development, finance, and commercial operations for the Company. • Streamlined R&D programs and development strategy to successfully prepare multiple NDAs for regulatory filings, resulting into 3 FDA approvals over an 18-month period. • Completed an upsized, top of the range $80M IPO in 2015, a $60M debt financing and two follow-on offerings, raising over $250M, and achieved a market cap of over $400M. • Built a world-class management team, a commercial organization with 50+ years of combined sales and marketing experience, and a 125-person field force. • Steered the Company through FDA approvals and commercial launches of multiple ADHD products, generating more than $75M in annual revenue within a span of less than two years. • Led several strategic negotiations, including settlement of Paragraph IV patent litigations with Shire and Teva.

Progressed a discovery-stage, emerging biotechnology company to a NASDAQ-listed, clinical-stage, drug development company. Responsible for all corporate planning, R&D, clinical, regulatory, finance and business development for both US and Canadian companies. Evaluated and executed new business initiatives, product development strategies and investment opportunities. Transitioned the Company from its initial focus on early research to a drug discovery and development company focused on the treatment of GI disorders. Built a world-class Board and management team including research, clinical and commercial leaders formerly from large Pharma. • Secured over $200M in capital using a variety of financial instruments, including a successful IPO in 2011. • Negotiated a partnership with Bristol-Myers Squibb and license agreement with a European partner totaling $50M in upfront payments, over $500M in milestones and double-digit royalties. • Led and managed the acquisition, financing, and integration of a Canadian drug discovery company. • Grew headcount from 5 to 45 employees with expanded research and development capabilities. • Built a pipeline of small molecule drug candidates for functional GI disorders and metabolic diseases, and advanced two molecules into late-stage (phase 2b and 3) clinical development. • Engaged investment bank and led a strategic review process that resulted in a successful merger with Ocera Therapeutics (NASDAQ: OCRX) in July 2013.

Full P&L responsibility for Company's US operations, R&D, business development and management. Led Company's product development, commercial and financing strategy. Raised over $50M in VC financing.

Responsible for product development and manufacturing operations. Played key roles in corporate development, financing and business development.

Responsible for marketing and presenting Company's technology and services to US, European and Japanese partners. Developed business strategy and established several funded collaborations with biotech and pharmaceutical companies.

Recombinant Proteins, Monoclonal Antibodies

Led a team of scientists developing industrial scale processes for protein expression and purification.